Back to News

Biodistribution and bioanalytical considerations for AAV based Gene Therapies Webinar - 26 March

Biodistribution and bioanalytical considerations for AAV based Gene Therapies Webinar - 26 March

February 23, 2021

IQ Webinar: Biodistribution, PK/PD and related bioanalytical considerations for AAV based Gene Therapies

Presenters: Kefeng Sun, PhD (Takeda) and Uma Kavita PhD (Bristol Myers Squibb)

Sponsored by the IQ Translational and ADME Sciences Cell and Gene/Nucleic Acid Based Modalities Working Group 

The biodistribution, PK/PD and analytical aspects are crucial for understanding both safety and efficacy of the AAV-based vector gene therapy (GT)  and is a component of the nonclinical package required by regulatory agencies prior to first-in-human trials.  
Discussion will include:

This webinar will provide a comprehensive overview of biodistribution and bioanalytical considerations and how concepts of “PK” apply for AAV based GTs. 

Click here for additional information and to register.